Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers
UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing novel therapies for a range of aggressive,...